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Background: Unexpected cholestasis substantially contributes to drug failure in clinical trials. Current models used
for safety assessment in drug development do not accurately predict cholestasis in humans. Therefore, it is of
relevance to develop new screening models that allow identifying drugs with cholestatic properties.
Methods: We employed mouse precision cut liver slices (PCLS), which were incubated 24 h with two model
cholestatic compounds: cyclosporin A (CsA) and chlorpromazine (CPZ). Subsequently, transcriptome analysis using
DNA microarrays and q-PCR were performed to identify relevant biological processes and biomarkers. Additionally,
histology was carried out and levels of triglycerides (TG) and bile acids (BA) were measured. To verify the ex vivo
mouse data, these were compared with publically available human data relevant for cholestasis.
Results: Whole genome gene expression analysis showed that CsA up-regulated pathways related to NF-κB, ER
stress and inflammation. Both CsA and CPZ down-regulated processes related to extracellular matrix (ECM)
remodelling, BA homeostasis, Fxr signalling, and energy metabolism. The differential expression of a number of
characteristic genes (e.g. Abcg5, Abcg8, Klf15, and Baat) could be confirmed by q-PCR. Histology revealed that CsA
but not CPZ induced “ballooning” of hepatocytes. No effects on TG and BA levels were observed after incubation of
PCLS with CsA and CPZ. A substantial number of processes altered in CsA- and CPZ-treated mouse PCLS ex vivo
was also found to be affected in liver biopsies of cholestatic patients.
Conclusion: The present study demonstrated that mouse PCLS can be used as a tool to identify mechanisms of
action of cholestatic model compounds. The induction of general stress responses and down-regulated Fxr
signalling could play a role in the development of drug induced cholestasis. Importantly, comparative data analysis
showed that the ex vivo mouse findings are also relevant for human pathology. Moreover, this work provides a set
of genes that are potentially useful to assess drugs for cholestatic properties.
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Drug induced liver injury is a major problem in medical
care and pharmacological industry. One example of severe
liver damage is cholestasis that comprises approximately
17% of all hepatic adverse drug reactions [1]. Cholestasis
results in a dramatic increase in liver and serum bile acids
that eventually can lead to liver failure [2]. Several currently
used drugs have been shown to induce cholestasis e.g.
cyclosporin A (CsA) used as an immunosuppressant is* Correspondence: ewa.szalowska@wur.nl
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reproduction in any medium, provided the orknown to induce cholestasis in human, rat and mouse [3,4],
and chlorpromazine (CPZ) applied as an antipsychotic was
shown to induce cholestasis in both human and rat [5]. It
is likely that CPZ can also induce cholestasis in mouse but
so far no studies addressing this issue have been reported.
Bile acids (BA) are amphipathic molecules synthesized
from cholesterol in hepatocytes, which together with
phospholipids and cholesterol are actively secreted by the
liver as bile. Upon a meal ingestion bile is released into the
intestinal lumen to enable absorption of dietary lipids and
fat-soluble vitamins [2]. BA levels are tightly controlled
because high BA concentrations may become cytotoxic [2].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the remaining part of the manuscript FXR symbol
will be used) is considered as a master regulator of BA
homeostasis. FXR upon BA binding regulates expression
of several genes involved in BA homeostasis in the liver
[2]. Impairment of FXR signaling and its downstream target
genes can result in intrahepatic cholestasis. For example,
dysregulation or mutations in genes encoding for bile
salt export pump (BSEP), multidrug resistance protein 3
(MDR3) [6], or cholesterol 7a-hydroxylase (CYP7A1) [7]
and bile acid-CoA:amino acid N-acyltransferease (BAAT)
can evoke cholestasis [8]. Other nuclear receptors (NRs),
such as pregnane X receptor (PXR), vitamin D (1,25-
dihydroxyvitamin D3) receptor (VDR), and constitutive
androstane receptor (CAR) are known to be involved
in BA detoxification by regulating expression of genes
involved in phase I and II reactions [9]. Moreover, FXR
also plays a major role in regulation of lipid and glucose
metabolism [2]. Therefore, FXR antagonism does not only
induce cholestasis but also leads to increased accumulation
of hepatic triglycerides [2]. For that reason, activation
of FXR is used in the treatment of cholestasis and non-
alcoholic steatohepatitis (NASH) [9].
Consistent with the fact that FXR is involved in both
BA and lipid metabolism, drug induced cholestasis can be
accompanied with the development of fatty liver diseases
[10]. It has also been postulated that drug-induced cho-
lestasis might lead to lipid accumulation as a secondary
event of endoplasmatic reticulum (ER) stress causing
mitochondrial dysfunction [11]. Additionally, inflammation
mediated by Kupffer cells and T cells can contribute to
progression of cholestasis [12]. Due to the complexity of
BA homeostasis and involvement of different cell types in
the development of cholestasis, it is difficult to study
this process in vitro. Precision cut liver slices (PCLS) are
commonly used as an in vitro/ex vivo liver model. The
major advantage of PCLS is that they contain native
liver architecture and all cell types characteristic for the
liver in vivo [13]. Additionally, it has been shown that
pathways mediated by FXR, VDR and PXR are also active
in rat and human PCLS, therefore supporting the use of
PCLS to study BA metabolism [13]. It has been reported
that studies employing toxicogenomics in PCLS can
correctly predict the toxicity and pathology observed
in vivo [14].
The main goal of the present study was to assess
whether application of mouse PCLS in combination with
whole genome gene expression profiling is an useful
approach to identify mechanisms leading to cholestasis. In
addition, we aimed to identify genes that could serve as
biomarkers to distinguish between cholestasis and other
types of hepatotoxicity such as necrosis and steatosis in
mouse PCLS. To that end, mouse PCLS were treated for
24 h with two known cholestatic drugs, CsA and CPZ,and subsequently subjected to DNA microarray analysis.
Transcriptome analysis was combined with biochemical
and histological examinations to allow comparison of the
array data with classical parameters of cholestasis.
Methods
Chemicals
Cyclosporin A, chlorpromazine, valproic acid, amiodarone,
paraquat, and isoniazid were purchased from Sigma
(Zwijndrecht, the Netherlands). Williams E medium
supplemented with Glutamax, penicillin/ streptomycin
(pen/strep), D-Glucose, PBS were obtained from Invitrogen
(Bleiswijk, the Netherlands).
Preparation and culture of liver slices
23-weeks old male C57BL/6 mice were obtained from
Harlan (Horst, The Netherlands). Animals were kept for
1 week at a housing temperature of 22°C and at a relative
humidity of 30–70%. The lighting cycle was 12-h light and
12-h dark. At the age of 24 weeks animals were sacrificed
by an overdose of isoflurane. The treatment protocol
was approved by the Ethical Committee for Animal
Experiments at Wageningen University.
Immediately after the animals were killed the liver was
perfused with PBS and placed in ice-cold Krebs–Henseleit
buffer (KHB) (pH 7.4, supplemented with 11 mM glucose).
Liver tissue was transported to the laboratory within
approximately 30 min and cylindrical liver cores were
produced using a surgical biopsy punch with diameter
of 5 mm (KAI, SynErgo Europe, Romania). Liver cores
were placed in a Krumdieck tissue slicer (Alabama
Research and Development, Munford, AL) filled with
ice-cold KHB aerated with carbogen and supplemented
with 11 mM glucose. Slices with a diameter of 5 mm, a
thickness of 0.2 mm and a weight of approximately 6 mg
were prepared. Immediately after preparation, slices were
transferred into culture plates filled with pre-warmed
(37°C) Williams E medium (WEM) supplemented with
pen/strep. Three liver slices were pre-cultured in one well
of the 6-well plate filled with 4 ml of WEM for one hour
with continuous shaking (70 rpm). Incubations were
performed in an oxygen controlled incubator (Galaxy 48 R
New Brunswick, Nijmegen, the Netherlands) at 80% of oxy-
gen; 5% CO2 and the remaining gas volume was filled up to
95% with N2. After one hour of pre-incubation, media were
removed and replaced with fresh media containing test
compounds or appropriate solvents. After incubations,
samples were snap-frozen in liquid nitrogen and stored
in −80°C for further analysis. Samples dedicated to histology
were stored in 4% formaldehyde at room temperature.
Cytotoxicity analysis (dose selection)
PCLS were exposed to different model compounds in-
ducing cholestasis, steatosis, necrosis, and to compounds
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selected based on literature search. As cholestatic model
compounds cyclosporin A (CsA), and chlorpromazine
(CPZ) were selected. For steatosis valproic acid [15] and
amiodarone [16] were selected. As pro-necrotic drugs
paraquat [17] and isoniazid [18] were used. To select a
non-toxic dose eventually to be used for the gene expres-
sion profiling experiments, the following concentrations
ranges were tested: cyclosporin A 0–100 μM, chlorpromaz-
ine 0–80 μM, valproic acid 0–500 μM, amiodarone 0–100
μM, paraquat 0–10 μM,and isoniazid 0–1000 μM,.
CyclosporinA, chlorpromazine, amiodarone, paraquat were
dissolved in DMSO, valproic acid was dissolved in ethanol
(EtOH), and isoniazid was dissolved in PBS. The com-
pounds were added to the culture medium at a final
concentration of 0.1% vol/vol in an appropriate solvent
(DMSO, EtOH, or PBS). Slices incubated with the solvents
at 0.1% vol/vol served as controls. Toxicity was assessed
with standard biochemical assays indicative for slices via-
bility: LDH, ATP, and protein assay. Dose selection experi-
ments were performed in slices obtained from at least two
mice (see also Additional file 1: Figure S1, Additional file 2:
Figure S2 and Additional file 3: Figure S3).
ATP and protein measurements
For each ATP and protein measurement a total of three
co-cultured slices were placed in 400 μL Cell Lytic MT
buffer (Sigma, Zwijndrecht, the Netherlands). In order
to compare ATP and protein content in liver slices from
different experiments, both ATP and protein were nor-
malized on mass of liver slices. In order to determine the
weight of the liver slices, three liver slices were removed
from the culture well. Thereafter, the three liver slices
were gently held in tweezers against a paper tissue for
2 seconds to let the tissue absorb the remaining medium.
Next, the three slices were weighed on a regular laboratory
balance and the mass was registered for each individual
exposure, which was 18 mg ± 25% for three slices. Slices
were homogenized (6500 g, 8°C) two times for 15 sec using
a tissue homogenizer (Precellys 24 Bertin Technologies,
Labmakelaar Benelux B.V. Rotterdam, The Netherlands).
To remove cellular debris, the homogenates were
centrifuged for 5 min (14000 g, 8°C) and the remaining
supernatant was divided into two portions of 200 μL.
One portion was stored at −80°C for protein measurements
and the second 200 μL portion was mixed with 100 μL of
ATP lytic buffer (ATPlite, Perkin Elmer, Oosterhout, The
Netherlands) for ATP measurements. ATP was measured
according to the manufacturer’s description using a micro-
plate reader (Synergy TM HT Multi Detection Microplate
Reader, Biotek Instruments Inc, Abcoude, the Netherlands)
with settings for luminescence: 590/635 nm, top meas-
urement, and sensitivity 230. ATP determination was
performed in technical duplicates and luminescencevalues were recalculated into μM ATP in total liver
slices extracts. ATP concentration was normalized on
mass of liver slices used for one ATP extraction.
The protein concentration was determined according to
the Bradford method (Protein assay, BioRad, Veenendaal,
The Netherlands). Protein samples of 2 μL were diluted
80 times in PBS and measured according to the manufac-
turer’s instructions. BSA was used as a standard and each
measurement was performed in duplicate. The protein
content was normalized on mass of liver slices used for
protein extraction.
Lactate dehydrogenase (LDH) assay
Lactate dehydrogenase activity in total tissue homogenate
and in the culture medium of each slice was performed
according to the manufacturer’s protocol (Cytotoxicity
Detection Kit (LDH), Roche Diagnostics, Almere, the
Netherlands). For the total LDH activity in slices, three
slices were homogenized (6500 g, 8°C) twice for 15 sec
using a tissue homogenizer (Precellys 24). Thereafter,
culture medium or the slice homogenate were diluted 5
fold with PBS and mixed with 100 μL reaction mixture
from the kit. After 15 minutes of incubation at room
temperature, samples were measured at 490 nm using a
Synergy TM HTMulti Detection microplate reader.
Triglycerides (TG) measurements
Three liver slices cultured together were used to make a
homogenate in 300 μL buffer containing 10 mM Tris,
1 mM EDTA (pH 7.4) and 250 mM sucrose. Aliquots of
10 μL of the liver slices homogenates were used in the
assay and measurements were performed according to the
manufacturer’s protocol (triglycerides liquicolor mono,
Instruchemie, Delfzijl, the Netherlands).
Bile acids measurements
For bile acids measurements, three slices were pooled and
placed in 400 μL Cell Lytic MT buffer (Sigma, Zwijndrecht,
the Netherlands). Slices were homogenized for two times
15 sec (6500 g, 8°C) using a tissue homogenizer (Precellys
24). Thereafter, the homogenates were centrifuged for
5 min (14000 g, 8°C) to remove cellular debris, and the
supernatant was used for measurements. Bile acids
quantification was performed according to the description
in manufacturer’s protocol (Total Bile Acid Assay Kit
Bioquant, Gentaur, Brussels, Belgium).
Histology
Slices were exposed for 24 and 48 hours to 40 μM CsA
or 20 uM CPZ. For the 48 hours cultures, after 24 hours
the culture medium was replaced with fresh medium.
Immediately after incubation, slices were fixed in 4%
buffered formaldehyde. After embedding in paraffin, cross-
sections were prepared, stained with haematoxylin and
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and examined under a microscope with a 100 x magnifica-
tion [19]. Fouchet staining for bile acids pigments and
Periodic acid-Schiff (PAS) for glycogen were performed
according to standard protocols (http://www.ihcworld.
com/histology.htm). For each condition slices obtained
from 5 mice were analysed. All pictures were taken
using 100-fold magnification.
PCLS exposure (gene expression profiling)
To obtain RNA for transcriptome analysis, PCLS were
cultured at the same conditions as described above. Slices
were exposed for 24 hours to one concentration of the
tested compounds or controls. Concentrations used in
the exposure experiments were pre-selected in the dose
selection experiments (cytotoxicity analysis). The highest
concentration that did not cause significant toxicity
assessed by biochemical assays (LDH, ATP, and protein
assay) was selected. The concentrations used in the ex-
posure experiments were as follows; for the cholestatic
exposures 40 μM CsA and 20 μM CPZ. For the
steatogenic exposures: 200 μM valproic acid, and 50 μM
amiodarone. For the necrotic compounds: 5 μM para-
quat and 1000 μM isoniazid. Liver slices obtained from
five mice were used in five separate experiments in
which exposures to toxic compound or vehicle control
were performed at the same time. Since dose selection
experiments and exposure experiments were performed
at different days, ATP, LDH, and protein assays were
performed again for the exposure experiments to confirm
that the selected doses did also not affect slice viability in
these experiments (Figure 1).
DNA microarray hybridizations
Gene expression analysis in liver slices incubated for
24 hours with the cholestatic, steatogenic, and necrotic
compounds as well as the controls was performed on
the HT Mouse Genome 430 PM array plate(s) using
the Affymetrix GeneTitan system. RNA was extracted
from three slices cultured and exposed together using the
RNeasy Tissue Mini Kit (Qiagen, Venlo, The Netherlands)
according to the manufacturer’s instructions. RNA con-
centration and purity were assessed spectrometrically
using a Nano Drop ND-1000 spectrophotometer (Isogen
IJsselstein, The Netherlands) by measuring absorption
ratios at 260/280 and 260/230 nm. The integrity of the
RNA samples was examined using the Shimadzu MultiNA
Bioanalyzer (Tokyo, Japan). Biotin- labelled cRNA was
generated from high-quality total RNA with the Affymetrix
3’IVT Express Kit (Affymetrix, Santa Clara, CA, USA)
according to the manufacturer’s specifications with an
input of 100 ng total RNA. The Agilent Bioanalyzer
(Amstelveen, the Netherlands) and Shimadzu MultiNA
Bioanalyzer (Tokyo, Japan) were used to evaluate thequality of cRNA in order to confirm if the average fragment
size was according to Affymetrix’ specifications. Per sample,
7.5ug cRNA of the obtained biotinylated cRNA samples
was fragmented and hybridized in a final concentration of
0.0375 ug /ul on the Affymetrix HT Mouse genome 430
PM array (Affymetrix, Santa Clara, CA, USA. After an au-
tomated process of washing and staining by the GeneTitan
machine (Affymetrix, Santa Clara, CA, USA) using the
Affymetrix HWS kit for Gene Titan, absolute values of
expression were calculated from the scanned array using
the Affymetrix Command Console v 3.2 software. The data
Quality Control was performed in the program Affymetix
Expression Console v 1.1 software to determine if all pa-
rameters were within quality specifications. The Probe
Logarithmic Intensity Error Estimation (PLIER) algorithm
method was used for probe summarisation [20].
In order to monitor the sample independent control
and the performance of each individual sample during
hybridization, hybridizations controls were added to the
hybridization mixture. The sample dependent controls
such as internal control genes, background values, and
average signals were used to determine the biological
variation between samples. In conclusion, all the data
were within data Quality Control thresholds, according
to Affymetrix Expression Console specifications. Non-
normalized data in a form of the Cell Intensity File
(*.CEL) were re-annotated (EntrezGene htmg430pm_
Mm_ENTREZG) and the data were RMA normalized
[20,21].
Gene Set Enrichment Analysis (GSEA)
In order to identify differentially expressed gene sets related
to diverse biological functions Gene Set Enrichment Ana-
lysis (GSEA) was applied. GSEA was performed using an
open access bioinformatics tool (http://www.broadinstitute.
org/gsea/index.jsp). In short, this method identifies bio-
logically and functionally related genes affected due to
experimental conditions. GSEA applies predefined gene
sets that are based on literature or other experiments.
Gene sets specify a group of genes specific for a certain
biological process, GO ontology, pathway, or user defined
groups. GSEA ranks all the genes on their expression ratios
between a treatment and the control group and determines
whether a particular gene set is significantly enriched at the
top or the bottom of the ranked list [22]. Gene sets used
in this study were created in an open access bioinfor-
matics tool ANNI http://www.biosemantics.org/index.
php?page=ANNI-2-0 [23]. ANNI retrieves all the infor-
mation available on known gene-gene associations present
in Medline and can be used, among others, to create gene
sets associated with simple queries, for example “inflam-
mation” or “cholestasis”. For the purpose of this study we
used several queries related to liver specific and liver non-

























































Figure 1 Biochemical characterization of mouse liver slices in exposure experiments. Liver slices were incubated for 24 hours with pre-
selected concentrations of cyclosporin A (CsA) 40 μM and chlorpromazine (CPZ) 20 μM. Protein content (A), ATP content (B) and LDH leakage
into medium compared to total LDH content in slices (C) were measured to assess liver slices viability. Ctr stands for control. Each point is the
mean ± SD of five independent experiments (liver slices were isolated from livers of five mice) and each measurement was performed in
technical duplicates. None of the measured parameters were significantly affected.
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file 4: Table S1. Genes present in at least five publications
indicating an association with the specified queries were
included in the ANNI gene sets.
For GSEA, also Gene Expression Omnibus microarray
data relevant for human cholestasis were used (GSE46960).
These gene expression data were generated in GeneChip®
Human Gene 1.0 ST array (Affymetrix, CA) hybridisation
experiments using human liver biopsies obtained from 64
infants with biliary atresia, 14 age-matched infants with
cholestasis of other origin than biliary atresia, and from 7
deceased-donor healthy children.
MetaCore pathway analysis
The GSEA report output file informs which gene sets are
significantly affected in the analysed groups. Additionally,
it informs, which genes significantly contribute to this
enrichment (significant genes). These significant genes
were used as an input for the MetaCore pathway analysis.
The pathway analysis was performed using Functional
Ontology Enrichment/ Pathways Maps default option in
MetaCore for mouse or human depending whether mouse
or human data were analysed, respectively. MetaCoreidentifies pathways using a default enrichment analysis.
The identified pathways were considered as significantly
affected by the treatment if p <0.005.
Biomarker identification
In order to identify biomarkers indicative for the develop-
ment of cholestasis, significant genes identified in GSEA
were subjected to Venn analysis. Genes overlapping
between CsA and CPZ treatments with absolute FC ≥1.5
were selected as potential biomarkers. Venn analysis was
performed using an open access tool http://bioinfogp.cnb.
csic.es/tools/venny/. Subsequently, biomarkers’ expression
values (derived from the DNA microarray data) were
compared with expression values for the same genes in
slices treated with non-cholestatic drugs. In order to do
so, the gene expression values were log2 transformed
and median centered followed by hierarchical clustering
using default options in Genesis (http://genome.tugraz.
at/genesisserver/genesisserver_description.shtml). Add-
itionally, the candidate biomarkers were uploaded to
another open access bioinformatics tool denoted with
Search Tool for the Retrieval of Interacting Genes/Proteins
8.2 (STRING) in order to perform functional clustering.
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based on known and predicted protein-protein interactions
[24]. Functional clustering of genes was performed in
STRING using functional clustering function.
q-PCR
In further studies, expression of ten candidate biomarkers
in PCLS was analyzed by q-PCR using the Biorad CFX96
TM Real-Time Detection System (Bio-Rad, Veenendaal,
The Netherlands) with the following cycling conditions:
15 min 95°C followed by 40 cycles of 15 s 95°C and 1 min
60°C. Reactions were performed in 10 μl and contained
20 ng cDNA, 1x TaqMan PCR Master Mix (Applied
Biosystems, Foster City, CA), and depending on the
analysed gene, 250 nM probe and 900 nM primer (for
actin b) or 1xTaqMan gene expression assay (for the
remaining genes) (Applied Biosystems, foster City, CA).
Specific primer set for actinβ (ACTB) was developed with
Primer Express 1.5 (Applied Biosystems, Nieuwerkerk aan
den IJssel, The Netherlands) and sequences were as fol-
lows, probe: TGT CCC TGT ATG CCT CTG GTC GTA
CCA C, forward primer: AGC CAT GTA CGTAGC CAT
CCA, and reverse primer: TCT CCG GAG TCC ATC
ACA ATG. Primers for Kruppel-like factor 15 (Klf15),
bile acid-CoenzymeA:amino acid N-acyltransferase (Baat),
ATP-binding cassette, sub-family G (WHITE), member 8
(Abcg8), ATP-binding cassette, and sub-family G (WHITE),
member 5 (Abcg5), were purchased from Applied Bio-
systems. The numbers of assays from Applied Biosystems
are given in Additional file 5: Table S2. Data were analyzed
with SDS 2.0 software (Bio-Rad). For each sample, the
RT-PCR reaction was performed in triplicate and the
averages of the obtained threshold cycle values (CT)
were processed for further calculations. To check for
contaminating DNA, samples without reverse transcriptase
(−RT reaction) were analysed as well. For normalization
ACTB was used. Relative expression was calculated with Δ
(Δ (CT))-method [25].
Statistical analysis
Mann–Whitney test was used to calculate differences
between controls and slices cultured with the tested
compounds for ATP, protein, LDH, TG, and bile acids.
The cut off for statistical significance was set at a
p-value < 0.05.
Mann–Whitney (MW) test was used to determine if
there was a significant difference in gene expression
assessed by q-PCR in slices exposed to different com-
pounds. A p-value <0.05 was considered significant.
Results
Exposure of PCLS to CsA and CPZ
In order to identify non-cytotoxic concentrations of
the model cholestatic compounds (CsA and CPZ), doseselection exposure experiments were performed. In these
experiments, PCLS were incubated for 24 hours with
four different concentrations of each drug. The applied
concentrations were for CsA 1, 2, 40, and 100 μM and
for CPZ 2, 4, 20, and 80 μM. Viability of the PCLS was
assessed by using LDH leakage, ATP, and protein content
as parameters. On the basis of the results from the viability
measurements, the highest concentration that did not
evoke significant decrease in viability was selected for
subsequent gene expression profiling experiments. The
results from the dose selection experiments are presented
in Additional file 1: Figure S1. With respect to CPZ, a
concentration of 20 μM was chosen for the microarray
experiment. Although CsA even at the concentration of
100 μM did not induce a decrease in viability, 40 μM was
selected for the microarray experiment since this concen-
tration was also used in other in vitro studies [26]. Results
from the dose selection experiments are presented in
Additional file 1: Figure S1A-C. Since the exposure for
gene expression profiling was performed with liver slices
from mice other than those used for dose selection, the
viability of these slices was tested as well. As shown in
Figure 1, it could be confirmed that 40 μM CsA and
20 μM CPZ did not affect the viability of the slices.
Transcriptome analysis: biological processes and pathway
analysis
Upon treatment of the slices for 24 h with 40 μM CsA
or 20 μM CPZ, RNA was isolated and hybridized to
DNA microarrays. In order to identify and to compare
significantly enriched processes, GSEA was performed
using gene sets made in the text-mining tool ANNI. The
gene sets (listed in Additional file 4: Table S1) were related
to diverse hepatic (e.g. lipid and glucose metabolism,
inflammation, bile acid metabolism) and non- hepatic
biological processes (e.g. adipogenesis, morphogenesis,
tight junctions). As indicated in Figure 2, CsA and CPZ
affected several of the gene sets/processes (p < 0.05,
FDR < 0.25). Both compounds down-regulated processes
related to cholesterol, bile acids, lipid, and glucose me-
tabolism. The gene set related to Kupffer cells was also
down-regulated by both compounds. CsA, but not CPZ,
up-regulated processes related to inflammation (such as T
cells, immunotoxicity, inflammation, and natural killer
cells) and molecular processes involved in cell death
(apoptosis, necrosis) and stress response (biological adap-
tation to stress, and sumoylation). Moreover, CsA down-
regulated processes related to cirrhosis and stellate cells
(Figure 2).
In order to get insight into the molecular mechanisms
of action of CsA and CPZ, the significantly altered genes
identified by GSEA (1192 and 811 genes for CsA and CPZ
respectively) were uploaded into MetaCore to identify
significantly altered pathways. In total, we identified 204
ANNI gene sets p<0.05 FDR<0.25 
Figure 2 Effects of cholestatic drugs on gene expression in
mouse PCLS. PCLS obtained from 5 mice were treated with 40 μM
cyclosporin A (CsA), 20 μM chlorpromazine (CPZ) or vehicle (DMSO)
for 24 hours and subjected to Affymetrix microarray analysis. The
biological processes in the heat map correspond to gene sets
significantly affected according to GSEA analysis (p < 0.05, FDR <
0.25). Gene sets were obtained using the ANNI text mining tool.
Processes that were up-regulated are represented by red color, the
down-regulated processes are depicted in green, processes that
were unchanged are depicted in black.
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respectively (p < 0.005) (Additional file 6: Table S3).
For a general overview of the processes affected by the
drugs, the identified pathways were grouped into broader
functional categories using a MetaCore pathway classifica-
tion output (Table 1, Additional file 6: Table S3). The
analysis based on the functional categories showed that
there was a substantial overlap between pathways affected
by the two drugs (Table 1). Both drugs affected pathways
related to immune function (immune response, chemo-
taxis), energy metabolism (pathogenesis of obesity, regula-
tion of metabolism), and other biological processes
(development, apoptosis and survival, signal transduction,
cell adhesion, G-protein signalling, protein folding and
processing). CsA affected additional functional categories,
such as cell cycle and DNA damage (Table 1). In a furtheranalysis, we focused on those pathways that according to
MetaCore pathway analysis, were found to be significantly
altered either by both drugs or specifically by one drug
(p < 0.005). Both CsA and CPZ altered Fxr-regulated
cholesterol and bile acids cellular transport (p = 6.8E-07
and p = 7.5E-08 respectively), Figure 3A, Additional file 6:
Table S3. In this pathway both CsA and CPZ significantly
down-regulated Fxr as well as its target genes involved in
BA transport such as solute carrier family 10 member
2 (Slc10a2) and multi-drug resistance 1/ ATP-binding
cassette, sub-family B, member 1 (Mdr1/Abcb1), Figure 3A.
ATP-binding cassette, sub-family C, member 2/ multidrug
resistance-associated protein 2 (Abcc2/ Mrp2), were
down-regulated only by CsA, while Bsep/ ATP-binding
cassette, sub-family B, member 11(Abcb11) and solute
carrier family 10 (sodium/bile acid cotransporter family),
member 1/ Na + −taurocholate cotransporting polypep-
tide (Slc10a1/Ntcp) were down-regulated only by CPZ
(Figure 3A). Moreover, both CsA and CPZ down-regulated
genes coding for cholesterol transporters such as Abcg5/
Abcg8 and Scavenger receptor class B member 1 (Sr-Bi) as
well as genes encoding for phospholipids transporter-
multidrug resistance 3/ ATP-binding cassette, sub-family B
(Mdr/Tap), member 4 (Mdr3/ Abcb4/Mdr2), (Figure 3A).
Another process significantly affected by both CsA and
CPZ is Bile acids regulation of glucose and lipid metabolism
via Fxr (p = 7.2E-14 and p = 1.1E-09 respectively), (Figure 3B).
Both, CsA and CPZ led to down-regulation of several
genes in this pathway, e.g. Fxr (Nr1h4), retinoid X re-
ceptor α (Rxrα), small heterodimer partner (Shp), hep-
atocyte nuclear factor 4 alpha (Hnf4α), apolipoprotein
B (Apob), very low-density lipoprotein (VLDL/Apoc2),
liver X receptor α (Lxr α). Furthermore, both CsA and
CPZ significantly down-regulated another pathway in-
volved in lipid homeostasis: Rxr-dependent regulation
of lipid metabolism via Ppar, Rar and Vdr (p = 5.8E-05
and p = 2.9E-04 respectively), (Figure 3C, Additional file 6:
Table S3).
In addition, CsA and CPZ significantly down-regulated
several genes of Cell adhesion_ECM remodelling pathway
(p = 1.3E-07 and p = 4.1E-09 respectively), (Figure 4,
Additional file 6: Table S3). Several metalloproteinases
were down-regulated by both drugs (Mmp-12, 15, 16),
as well as other genes involved in ECM remodelling
(Syndecan-2, Egfr).
One of the most significantly affected pathways by CsA
was the Endoplasmic reticulum stress response pathway
(p =1.8E-13), (Apoptosis and survival), Additional file 6:
Table S3, Additional file 7: Figure S4. Several genes present
in this pathway were up-regulated, such as NF-κB p50/p65,
Grp78, Ire-1, and Traf2. Additionally, CsA affected several
pathways related to NF-κB signalling and inflamma-
tion, such as NF-κB signaling (p = 4.2E-11), Il-1 signaling
pathway (p = 7.8E-11), and Hsp60 and Hsp70 Tlr signaling
Table 1 Overview of pathway functional categories







Immune response 58 27
Development 53 41
Pathogenesis of obesity 23 16
Apoptosis and survival 18 6
Signal transduction 16 12
Regulation of metabolism 10 8
Cell cycle 5 0
Cell adhesion 4 8
G-protein signaling 4 2
Protein folding and processing 4 2
Chemotaxis 3 1
Cytoskeleton remodeling 3 2
DNA damage 2 0
Reproduction 1 0
Pathways identified in MetaCore were grouped into functional categories
according to the MetaCore classification tool (first column). The number of
affected pathways within the functional categories is presented in separate
columns for cyclosporin A (CsA) and chlorpromazine (CPZ). MetaCore analysis
revealed a total of 204 (CsA) and 125 (CPZ) significantly altered pathways
(p < 0.005). All identified pathways are presented in Additional file 6: Table S3.
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Additional file 8: Figure S8A-C). In general we observed
up-regulation of different NF-κB partners (NF-κB p65,
p100, p52) and pro-inflammatory cytokines exampled by
Tnfα or Il-12.
Identification of biomarkers
In order to identify biomarkers that could be used for
identification of drugs with cholestatic properties, genes
were selected that, according to GSEA, significantly
contributed to the enrichment of the analysed gene sets
(p < 0.05, FDR < 0.25) in both CsA and CPZ treatments. In
total 305 common candidate biomarkers were identified
and further selection using FC ≥1.5 as criterion resulted in
73 genes. These genes could be categorized in five func-
tional clusters: β-oxidation, biotransformation, BA metab-
olism, BA conjugation, and lipid metabolism (Figure 5).
Hierarchical clustering of these genes, led to a very good
separation between control and slices treated with CsA
(Figure 6A). CPZ treated samples separated very well
except for one control and one treated sample, which
were mis-classified (Figure 6B). Furthermore, we analysed
the expression levels of these 73 genes in liver slices
exposed to two other classes of hepatotoxicants, i.e.
steatogenic drugs (valproic acid and amiodarone) and
necrotic drugs (paraquat and isoniazid). In contrast to the
slices exposed to CsA and CPZ, hierarchical clustering of
array data (of the 73 selected genes) from slices exposedto steatogenic (Figure 6C-D) and necrotic compounds
(Figure 6E-F) did not show a clear separation between
treatment and control.Microarray data verification (qPCR)
For verification of the array data, 4 genes out of the 73
potential biomarkers were subjected to qPCR. These
genes were Baat, Abcg5, Abcg8, and Klf15. The major
criterion for the selection of these genes was related to
their function in Fxr signalling. Three of these four
genes are related to BA metabolism and are targets of
Fxr/Nr1h4 [2]. Moreover, mutations in Baat, Abcg5 or
Abcg8 have been shown to be involved in the development
of cholestasis in humans [2,8]. Although Klf15 is not a
Fxr target, it is known to be involved in gluconeogenesis
[27], which is regulated by Fxr [28,29]. More detailed
information about the functions of the selected genes
is presented in Additional file 9: Table S4. The qPCR
experiments were performed on the same RNAs as used
for the DNA microarray hybridisations. Statistical analysis
of the qPCR data showed that CsA and CPZ significantly
affected 3 out of the 4 candidate biomarkers (Table 2A-B).
In slices exposed to necrotic and steatogenic drugs the
expression of at most one out of the four genes was
significantly affected (Table 2C-F).Biochemical and histological analysis
Slices cultured for 24 and 48 hours with the reference
compounds and controls were subjected to histological
analysis. Upon incubation for 24 hours, some hepatocytes
localized in the outer part of slices treated with CsA had
developed a characteristic ballooned phenotype, which
was even more evident after 48 hours and was absent in
control slices. These hepatocytes were enlarged compared
to control and had their nucleus in the centre (Figure 7).
Based on the histological examination as well as transcrip-
tome data analysis, showing alternations in lipid and BA
metabolism, it could be envisaged that the enlargement of
cells treated with CsA is due to TG or BA accumulation.
Therefore, biochemical assays to quantify TG and BA levels
were employed. However, compared to control, no increase
of BA or TG in CsA treated slices was observed (Figure 8A
and B). Additionally, we performed Periodic acid-Schiff
(PAS) staining to detect glycogen, which theoretically could
also accumulate in hepatocytes and lead to their en-
largement. As expected, control slices showed substantial
number of cells containing glycogen (Figure 8C). However,
in the enlarged cells of the CsA treated slices no glycogen
could be detected (Figure 8D). Finally, Fouchet staining
was performed to examine whether CsA treatment resulted
in the accumulation of bile, a process that is often
accompanying cholestasis. Although, we did not detect bile
accumulation in slices, Fouchet staining unexpectedly
Figure 3 Effects of cyclosporin A and chlorpromazine on the expression of genes involved in Fxr and Rxr-regulated pathways related
to metabolism and/or transport of bile acids and lipids. Cyclosporin A (CsA) and chlorpromazine (CPZ) significantly affected Fxr-regulated
cholesterol and bile acids cellular transport pathway (A), Bile acids regulation of glucose and lipid metabolism via Fxr (B), and Rxr-dependent
regulation of lipid metabolism via Ppar, Rar and Vdr pathway (C). Blue and red bars indicate down-and up-regulation respectively of significantly
affected genes. 1 and 2 indicate liver slices treated with CsA and CPZ respectively. Each bar represents average fold change of gene expression
(treatment vs. control) in liver slices from five mice. ECM: extracellular matrix. For an explanation of the MetaCore symbols is referred to http://
pathwaymaps.com/pdf/MC_legend.pdf.
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absent in control slices (Figure 8E and F).
Comparative data analysis: relevance for human
pathology
In order to verify whether the results on drug induced
cholestasis in mouse liver slices would also be observed
in patients suffering from cholestasis, publically available
transcriptomics data were analysed. The data were gener-
ated using liver biopsies obtained from children sufferingfrom biliary atresia, intrahepatic cholestasis of other origin
than biliary atresia, and age-matched controls. GSEA
revealed that patients suffering from both biliary atresia and
intrahepatic cholestasis had significantly down-regulated
gene sets related to different aspects of energy metabolism
including bile acid metabolism, FA metabolism or peroxi-
somes. These changes were in line with drug-induced
cholestasis in mouse PCLS (Figure 9). However, gene
sets related to ECM, angiogenesis, and fibrosis were
up-regulated in the livers of cholestatic patients but
Figure 4 Effects of cholestasis on the expression of genes involved in the Cell adhesion_ECM remodelling pathway and in mouse
PCLS. Both cyclosporin A (CsA) and chlorpromazine (CPZ) significantly affected the Cell adhesion_ECM remodelling pathway (p < 0.005).
Explanation of the bars is given in the legend of Figure 3.
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the opposite direction by the tested drugs in mouse liver
slices (Figure 9). MetaCore pathway analysis showed that
FXR signalling such as Bile acids regulation of glucose and
lipid metabolism via FXR (Additional file 10: Figure S6A)
and FXR-dependent negative-feedback regulation of bile
acids concentration (Additional file 10: Figure S6B) were
significantly down-regulated in cholestatic patients. These
latter two pathways were also found to be down-regulated
in the mouse slices experiment (Figure 3). Furthermore,not only GSEA but also MetaCore analysis showed
that the pathway ECM remodeling was up-regulated
(Additional file 11: Figure S7). This pathway was down-
regulated by CsA -and CPZ-treatment in mouse PCLS
(Figure 4).
Discussion
In the present study, we aimed to assess whether mouse
PCLS can be used as an ex vivo model to study processes
related to the development of drug-induced cholestasis.
Figure 5 Functional clustering of biomarkers. In total 73 genes were identified as candidate biomarkers for drug-induced cholestasis.
Clustering of biomarkers was performed in STRING using the functional clustering option. The analysis identified 5 functional clusters; yellow
represents β-oxidation, blue represents biotransformation, brown represents bile acids and drugs conjugation, green represents lipid metabolism,
and red regulation of bile acids metabolism via Fxr (Nr1h4). A total of 46 out of 73 genes formed connected nodes. Disconnected genes
(27genes) were removed from the figure.
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to induce cholestasis in vivo in humans and rodents. In
depth transcriptome analysis combined with biochemical
and histological evaluation were performed to identify early
molecular events and biomarkers that can be used to
screen drugs for cholestatic properties.Exposure of PCLS to CsA and CPZ
The effects of CsA and CPZ were analysed upon treatment
of PCLS with 40 μM CsA and 20 μM CPZ. These concen-
trations were relatively high compared to plasma levels
of patients chronically treated with the same drugs, i.e.
0.04-0.1 μM for CsA [26] and 0.02-0.3 μM for CPZ [30],
but similar concentrations were used in other in vitro
studies [30,31] and the applied concentrations did not
cause a decrease in slices viability assessed ATP and
LDH assays.However, GSEA analysis on the transcriptome data
revealed that CsA induced a higher number of processes
indicative for cytotoxicity such as apoptosis, necrosis, or
inflammation than CPZ (Figure 2). This could indicate
that the applied concentration of CsA was toxic, although
according to the viability tests (ATP and LDH assays)
doses even higher than 40uM did not cause a significant
decrease in viability (Additional file 1: Figure S1). These
results suggest therefore, that ATP as well as LDH mea-
surements may not always be reliable to predict cytotoxic
concentration of drugs. In addition, due to known inter-
species differences for toxic doses of drugs, application
of drug concentrations identical to in vitro studies
using different species, seems to be inappropriate as
well [32,33]. On the other hand, we cannot exclude that
the cytotoxic processes are due to pharmacological
actions of CsA, because other in vitro studies de-
monstrated that also lower CsA concentrations induce
Figure 6 Identification of potential biomarkers for cholestasis in PCLS. PCLS were exposed for 24 hours to model toxicants for cholestasis
(cyclosporin A (CsA)-A, chlorpromazine (CPZ)-B), steatosis (amiodarone (A)-C, valproic acid (VA)-D, necrosis, isoniazid (ISND-E), paraquat (PQ)-F,
and controls (ctr)). GSEA led to the identification of 73 genes for which the mRNA expression was down-regulated by both CsA and CPZ. mRNA
expression values for the selected biomarkers are derived from DNA-microarrays and results are presented as heat maps of log2, median centered
gene expression values. Red and green indicate expression higher or lower respectively than the average expression of all samples within the
same heat map. Please note Fxr is also depicted as Nr1h4.
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and cystic fibrosis [26].
Subsequent detailed pathway analysis revealed that both
CsA and CPZ significantly altered pathways (p < 0.005)
governed by Fxr including Fxr regulated cholesterol and BAs
cellular transport (Figure 3A, Additional file 6: Table S3)
and BA regulation of glucose and lipid metabolism via Fxr
(Figure 3B, Additional file 6: Table S3). Both drugs down-
regulated several transporters involved in bile production
and BA secretion: Mdr1, Abcg5/Abcg8, as well as Mdr3
(Mdr2). This is in agreement with a previous rat PCLS
study, which showed that CsA reduced Mdr1 activity [30].
Furthermore, we observed that CsA down-regulated
another BA transporter, Mrp2 (Abcc2). These data are
in line with observations made in rats showing that the
same transporters were down-regulated by CsA in the
liver at the protein level [34]. With regard to CPZ we
detected down-regulation of Fxr targets such as Bsep,
Mdr3, Ntcp (Slc10a1), and Cyp8b1. These findings are in
agreement with a recent study showing a down-regulation
of the same genes in CPZ-treated HepaRG cells [35].
The importance of Fxr signalling in the maintenance of BA
homeostasis in vivo is unequivocal and it was demonstrated
that Fxr knockout mice have disturbed BA homeostasis[36]. Moreover, we observed that both CsA and CPZ
down-regulated several genes related to lipid metabolism
(e.g. Hnf4α, Apob, Apoc, Hnf3, or Pparα) [2] in BA regu-
lation of glucose and lipid metabolism via Fxr pathway
(Figure 3B, Additional file 6: Table S3). Consistent with
these observations, it was reported that CsA treatment led
to an increase in accumulation of lipid droplets in rat
primary hepatocytes after 24 hours [37] and CsA therapy
has been implicated in the development of fatty liver [38].
Next to that, CPZ has been shown to inhibit β-oxidation
in vivo [39] and to evoke an increase in microsomal
phospholipidosis in rats [40]. However, based on biochem-
ical measurement of TG in our study, we concluded that
no lipids accumulated in CsA or CPZ treated slices. Based
on the outcome of the present work, we propose that
CsA and CPZ down-regulate Fxr signalling resulting in
perturbation of BA, glucose, and lipid metabolism, which
eventually leads to the development of both cholestasis
and metabolic disorders. This is in line with the known
functions of Fxr related to the regulation of both BA and
energy homeostasis [10,36] and common side effects of
CsA and CPZ treatments, i.e.cholestasis, fatty liver, and
type 2 diabetes [38,40]. Additionally, we detected that
both CsA and CPZ down-regulated other NRs involved in
Table 2 Validation of potential biomarkers for cholestasis in PCLS
A B
Drug CsA CsA CsA CsA CsA MW test Drug CPZ CPZ CPZ CPZ CPZ MW test
Gene FC1 FC2 FC3 FC4 FC5 Gene FC1 FC2 FC3 FC4 FC5
ABCG5 −3.5 −1.8 −1.0 −1.3 −1.2 NS ABCG5 −4.2 −2.9 −6.7 −3.8 1.0 *
ABCG8 −4.9 −3.9 −1.2 −2.0 −1.2 * ABCG8 −2.9 −2.1 −5.4 −4.5 −1.1 *
BAAT −5.2 −4.2 −1.6 −2.2 −1.7 * BAAT −2.3 −3.3 −8.5 −6.4 1.4 *
KLF15 −1.2 −1.7 −2.0 −1.4 −1.3 * KLF15 −2.0 −1.8 −3.2 −1.8 1.6 *
C D
Drug A A A A A MW test Drug VA VA VA VA VA MW test
Gene FC1 FC2 FC3 FC4 FC5 Gene FC1 FC2 FC3 FC4 FC5
ABCG5 1.2 −1.6 1.2 1.1 −1.3 NS ABCG5 2.0 −1.7 −1.1 1.4 1.6 NS
ABCG8 2.0 −1.6 1.1 1.1 −1.1 NS ABCG8 2.2 −1.5 −1.3 1.4 1.9 NS
BAAT 1.8 −2.2 1.1 −1.0 −1.7 NS BAAT 1.3 1.0 −2.0 1.4 2.5 NS
KLF15 2.6 −1.8 −1.5 −1.4 −1.3 NS KLF15 1.0 −1.9 −1.7 −1.1 1.1 NS
E F
Drug ISND ISND ISND ISND ISND MW test Drug PQ PQ PQ PQ PQ MW test
Gene FC1 FC2 FC3 FC4 FC5 Gene FC1 FC2 FC3 FC4 FC5
ABCG5 2.0 3.0 1.1 2.0 2.0 * ABCG5 1.1 1.1 1.7 −1.3 −1.6 NS
ABCG8 2.1 2.8 1.0 2.3 1.9 NS ABCG8 1.0 −1.2 1.8 −1.3 −1.4 NS
BAAT 1.8 1.7 1.1 −1.3 1.3 NS BAAT −1.2 −1.0 1.7 1.1 −1.4 NS
KLF15 1.2 2.4 1.0 1.1 1.2 NS KLF15 1.3 −1.0 1.3 1.1 −1.2 NS
PCLS were exposed for 24 hours to model toxicants for cholestasis (cyclosporin A (CsA)-A, chlorpromazine (CPZ)-B), necrosis (isoniazid (ISND)-C, paraquat (PQ)-D),
and steatosis (amiodarone (A)-E, valproic acid (VA)-F). Q-PCR was used to measure mRNA expression relative to actin β of four potential biomarkers: Abcg5, Abcg8,
Baat, and Klf15. FC stands for fold change (treatment vs. control). Q-PCR was performed for liver slices obtained from five biological replicates. Asterisk (*)
indicates significantly different gene expression (P < 0.05) from controls according to Mann–Whitney-test (MW). NS stands for not significant.
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(Nr1i3), Vdr and other genes related to lipid metabolism
such as Cpt1a and Hmgcs2 [9], (depicted in Rxr-dependent
regulation of lipid metabolism via Ppar, Rar and Vdr
pathway, Figure 3C, Additional file 6: Table S3). Down-Figure 7 Histological analysis of liver slices treated with CsA and CPZ
(control) (A and B), 40 μM CsA (C and D) or 20 μM CPZ (E and F). Histolog
outer parts of slices after 24 and 48 hours (C and D respectively). Histology
respectively) revealed a slight increase in number of cells containing pycnoregulation of these genes possibly adds to the cholestatic
and lipogenic properties of the analysed drugs.
Furthermore, for both CsA and CPZ, significant alterna-
tions in ECM remodelling pathway were found (Figure 4).
It was suggested before, that changes related to ECM. PCLS were cultured for 24 and 48 hours in the presence of DMSO
y of PCLS treated with CsA revealed ballooning of hepatocytes at the
of CPZ treated slices cultured for 24 and 48 hours (E and F




































Figure 8 Biochemical analysis and specific histological staining of liver slices treated with CsA. Bile acid (BA) (A) and triglyceride (TG) (B)
levels in PCLS cultured for 24 or 48 hours in the presence of either DMSO or 40 μM cyclosporin A (CsA) were not affected by any of the
conditions, X- axis represents the tested conditions and Y-axis represents content of BA (A) or TG (B) in nmol per slice. Glycogen was assessed by
PAS staining in PCLS cultured for 24 h in the presence of DMSO (C) or 40 μM CsA (D) demonstrating the absence of glycogen in ballooning
hepatocytes. Arrows in (C) indicate the presence of glycogen in controls. Fouchet staining in PCLS cultured for 24 h in the presence of DMSO (E)
or 40 μM CsA (F) demonstrating accumulation of several vacuoles in CsA treated slices (see arrows in F). All pictures were taken using
100-fold magnification.
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http://www.biomedcentral.com/1755-8794/6/39remodelling could lead to perturbations in intracellular
signalling affecting Fxr related pathways and thereby
leading to liver injuries [41].
Transcriptome data analysis also revealed processes and
pathways that were specifically affected by either CsA or
CPZ. CsA treatment up-regulated pathways and genes
related to endoplasmic reticulum (ER) stress (Additional
file 7: Figure S4), NF-κB signalling, and inflammation
with upregulated cytokines such as Tnfα, Crp, and Il-1β
(Additional file 8: Figure S5A-C). These findings are in
line with previous reports describing ER stress and inflam-
mation as the primary events in CsA induced toxicity
[42,43]. ER stress is known to activate NF-κB, which is
a key regulator of diverse immune responses [44].
Moreover, we found that CsA up-regulated gene sets
related to T cells. This contrasts to findings that CsA
inhibits T-cell receptor signalling and induces Tgfβ, which
both prevent the production of cytokines and block the im-
mune system [42]. Inasmuch as CsA caused up-regulation
of gene sets related to functions of T cells, the immunosup-
pressive effects of CsA in our model, seem to be different
compared to CsA effects in vivo. A possible cause could
be the relatively short time of this study or a lack of blood
immune cells which interactions with the liver immune
cells are necessary to fully develop the immune response
[45]. To the best of our knowledge, there is only one report
describing presence and actions of T cells in human liverslices [46]. Therefore, the exact biological meaning of the
CsA effect on gene expression specific to T-cells in mouse
PCLS remains to be elucidated in the future. Additionally,
CsA down-regulated the expression of several genes en-
coding heat shock proteins (HSP) (e.g. Hspb6, Hsph1,
Hspe1) as well as Sec proteins (Sec61a1, Sec14l2, Sec14l4)
(shown in Additional file 12). HSP proteins and Sec
proteins are involved in folding/ unfolding of proteins
and protein translocation, respectively [47,48]. It is
known that ER stress induced by CsA negatively affects
the function of the HSP and Sec proteins that eventually
lead to perturbations in protein and bile secretion [49,50].
Also the vacuolisation in CsA treated slices, as shown
in the present study by Fouchet staining, could be a
consequence of this disturbance in protein folding and
translocation/ secretion [26,49,51].
The up-regulation of ER stress, NF-κB signalling and
expression of pro-inflammatory cytokines (e.g. Tnfα, Crp,
Il1β) by CsA could be the cause of the observed down-
regulation of Fxr and its gene targets as well as other
nuclear receptors. Previously it has been shown that
the NF-κB-mediated acute phase response induced by
lipopolysaccharide (LPS) is associated with a decrease
of Fxr expression in mouse liver [52]. Furthermore, TNFα
and IL1β treatment of Hep3B human hepatoma cells and
mice resulted in decreased expression of RXRα, PPARα,
PPARγ, LXRα, as well as their co-activators PGC1α and
Figure 9 Effects of cholestasis on gene expression in human liver biopsies. A publically available transcriptomics data set (GSE46960) of liver
biopsies obtained from 64 infants with biliary atresia, 14 infants with intrahepatic cholestasis of other origin than biliary atresia, and 7 age-
matched controls were subjected to GSEA. The biological processes in the heat map correspond to gene sets significantly affected according to
GSEA analysis (p < 0.05, FDR < 0.25). Gene sets were obtained using the ANNI text mining tool. Processes that were up-regulated are represented
by red color, the down-regulated processes are depicted in green, and processes that were unchanged are depicted in black.
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modulations in hepatic energy homeostasis [53].
Although CPZ did not induce oxidative stress based
on transcritpome data, it is likely that it is also a trigger
to down-regulate Fxr signaling at early time points that
we did not test. Consistent with this notion, it was shown
that CPZ induces oxidative stress in HepaRG cells alreadyafter 30 min resulting in down-regulation of FXR-target
genes after 24 hours [35].
Moreover, we observed that CPZ and CsA down-
regulated gene sets related to Kupffer cells (Figure 2)
pointing out towards known immunosuppressive actions
of CPZ and CsA [54]. Analysis of the microarray data to
identify potential biomarkers for cholestasis showed a
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static compounds from non-cholestatic hepatotoxicants
(Figure 6A-F). Functional clustering of these potential
biomarkers identified processes such as β-oxidation, bio-
transformation, BA metabolism and conjugation, and lipid
metabolism. To verify the gene expression data obtained
with microarrays, q-PCR was performed on genes involved
in processes governed by Fxr i.e. BA homeostasis and
gluconeogenesis [2,27,29]. The expression of the selected
biomarkers as assessed by q-PCR was similar to that of
the microarray analysis (Tables 2 A-F). To further validate
the potential of these genes (Figure 6) to screen for chole-
stasis additional studies are required using more reference
compounds and models.
Biochemical and histological analysis
Based on the transcriptome data, it was expected that
TG or BA levels would be altered in PCLS upon the
treatment with CsA and CPZ. However, this could not
be confirmed by biochemical and histological assays.
Fouchet staining, reacting with bilirubin is not suitable
to identify bile accumulation ex vivo probably due to
lack of bilirubin derived from broken heme that in vivo
reaches the liver via the blood. On the other hand, H&E
staining demonstrated that CsA, but not CPZ, induced
ballooning of hepatocytes. This phenotype is generally
regarded as a form of apoptosis in the context of inflamed
fatty liver (steatohepatitis) caused by obesity, alcohol or
other toxic compounds [55,56]. This phenotype could
be associated with the up-regulation of gene sets related
to apoptosis and inflammation observed in CsA treated
slices.
It has to be underlined that the mouse PCLS experiments
were performed without supplementing the media with
BA. On the one hand this might explain the absence of BA
accumulation in the slices upon treatment with CsA
and CPZ. On the other hand, by leaving out BA from
the culture medium, we have identified early events in-
volved in the development of CsA- and CPZ-induced cho-
lestasis rather than indirect effects associated with a late
cholestatic phenotype, such as toxic BA accumulation.
Relevance of the mouse PCLS findings for human
Due to the lack of transcriptomic data of cholestatic
livers from patients treated with CsA and CPZ, we used
publically available data of livers of patients suffering
from cholestasis due to biliary atresia and other causes.
The comparison of the gene expression profiles of drug-
induced cholestasis in mouse PCLS and livers of cholestatic
patients pointed to several processes that were similarly
affected. These processes are associated with energy me-
tabolism and include lipid, BA metabolism, and glucose
metabolism, among others (Figure 9, Additional file 10:
Figure S6). The comparative analysis thereby indicatesthat mouse PCLS are a valid model to study mechanisms
involved in the development of human cholestasis. The
opposite direction in regulation of gene sets and pathways
related to ECM, angiogenesis and fibrosis between livers of
cholestatic patients and mouse PCLS (Figure 9, Additional
file 11: Figure S7) could be explained by obvious differences
related to e.g. chronic pathological conditions in vivo
vs. short time experiments in PCLS. The same is true
for up-regulation, only in patients, of other gene sets
related to liver carcinoma, angiogenesis or fibrosis
(Figure 9) that, in order to develop, require long-term
processes as well as multi-organ and blood cells interac-
tions [2,57]. Consistent with these notions, it was also
reported that cholestasis and other chronic liver diseases
are associated with the development of fibrosis caused by
accumulation of ECM [58].
However, whether oxidative stress and subsequent down-
regulation of NRs involved in the maintenance of BA
and energy homeostasis are the common links between
drug-related cholestasis in mouse (PCLS) and drug-
unrelated cholestasis in humans, remains to be resolved
in the future, when more appropriate human data will be
available.Conclusion
In summary, our study demonstrates that mouse PCLS
can be used as a tool to identify mechanisms of action of
cholestatic compounds. Based on the transcriptome
analysis it is proposed that CsA and CPZ affect pathways
involved in general stress responses, such as ER stress
(CsA), NF-κB-mediated responses (CsA), and ECM remod-
elling (CsA and CPZ) associated with down-regulation of
Fxr signalling, a key process in BA and lipid homeostasis.
Importantly, gene expression pattern in livers of cholestatic
patients displayed several similarities to PCLS treated
with model cholestatic compounds, indicating that some
common mechanisms are involved in the development of
cholestasis both in human pathology and mouse PCLS.
Moreover, this work provides a set of genes that are
potentially useful to screen compounds for Fxr-mediated
cholestatic properties.Additional files
Additional file 1: Figure S1. A-F. Dose selection experiments for
cholestatic drugs. Biochemical viability assays in liver slices after 24 hours
exposure to cyclosporin A (CsA) and chlorpromazine (CPZ). Liver slices
were incubated for 24 hours and exposed to different concentrations of
cyclosporin A (CsA) (0–100 μM) or chlorpromazine CPZ (0-80uM) and
compared to 0.1% DMSO control. Slices viability was assessed by protein
content for CsA and CPZ (A and B respectively), ATP content for CsA
and CPZ (C and D respectively) and LDH leakage for CsA and CPZ (E and F
respectively). Each point is ± SD of two independent experiments (liver slices
were isolated from livers of two mice, additionally for each measurement
three technical replicates were used). Error bars represent ± SD.
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http://www.biomedcentral.com/1755-8794/6/39Additional file 2: Figure S2. A-C. Dose selection experiments for
steatogenic drugs. Biochemical viability assays in liver slices after 24 hours
exposure to amiodarone (A) and valproic acid (VA). Liver slices were
incubated for 24 hours and exposed to different concentrations of A
(0–100 μM) or VA (0–500 μM) and compared to corresponding controls.
Slices viability was assessed by protein content, ATP content and LDH
leakage. Each point is ± SD of five independent experiments (liver slices
were isolated from livers of five mice, additionally for each measurement
two technical replicates were used).
Additional file 3: Figure S3. A-C. Dose selection experiments for necrotic
drugs. Biochemical viability assays in liver slices after 24 hours exposure to
isoniazyd (ISND) and paraquat (PQ). Liver slices were incubated for 24 hours
and exposed to different concentrations of ISND (0–1000 μM) or PQ
(0–10 μM) and compared to corresponding controls. Slices viability was
assessed by protein content, ATP content, and LDH leakage. Each point is ± SD
of five independent experiments (liver slices were isolated from livers of five
mice, additionally for each measurement two technical replicates were used).
Additional file 4: Table S1. ANNI gene sets.
Additional file 5: Table S2. List of primers used for q-PCR.
Additional file 6: Table S3 Total pathway analysis. Pathway analysis led
to identification of 204 and 125 significantly altered pathways for CsA
(A) and CPZ (B) (p < 0.005). Pathways were grouped into functional
categories according to MetaCore pathways classification (first column).
Each functional category contains pathway name and p value.
Additionally number of significantly affected genes and total number of
gene in pathways are given. Pathways that were discussed in the paper
in details are in bold and underlined.
Additional file 7: Figure S4. MetaCore pathway analysis in CsA treated
slices: Endoplasmic reticulum stress response pathway. Cyclosporin A
(CsA) significantly affected Endoplasmic reticulum stress response pathway
(p < 0.005). Blue (down-regulation) and red (up-regulation) bars indicate
significantly affected genes. The numbers 1–5 represent fold change
(treatment vs. control) of gene expression of five independent
experiments (i.e. liver slices isolated from 5 mice).
Additional file 8: Figure S5. MetaCore pathway analysis in CsA treated
slices: Nf-κB signaling Il-1 signaling pathway, and Hsp60 and Hsp70 Tlr
signaling pathways. PCLS treated with CsA displayed significant
(p < 0.005) up regulation of NF-κB signaling (A, Il-1 signaling pathway (B), and
Hsp60 and Hsp70 Tlr signaling pathways (C). Blue (down-regulation) and red
(up-regulation) bars indicate significantly affected genes. The numbers 1–5
represent fold change (treatment vs. control) of gene expression of five
independent experiments (i.e. liver slices isolated from 5 mice).
Additional file 9: Table S4. Functions of genes tested by q-PCR, source
GeneCards http://www.genecards.org.
Additional file 10: Figure S6. A-B. Effects of cholestasis on the
expression of genes involved in Fxr-regulated pathways related to lipid
and bile acids metabolism in human liver biopsies. Both biliary atresia
and intrahepatic cholestasis significantly down-regulated Bile acids
regulation of glucose and lipid metabolism via Fxr (A), and Fxr-dependent
negative-feedback regulation of bile acids concentration (B). Blue and red
bars indicate down-and up-regulation respectively of significantly
affected genes. The bar numbers 1 and 2 indicate liver biopsies obtained
from patients suffering from biliary atresia and intrahepatic cholestasis,
respectively. Each bar represents average fold change of gene expression
(disease vs. control) in liver biopsies. For an explanation of the MetaCore
symbols is referred to http://pathwaymaps.com/pdf/MC_legend.pdf.
Additional file 11: Figure S7. A. Cell adhesion ECM remodelling pathway is
affected in liver biopsies of patients suffering from cholestasis. In two types of
human cholestasis, biliary atresia (bar 1) and intrahepatic cholestasis (bar 2)
both Cell adhesion_ECM remodelling pathway (p < 0.005) (A) was affected.
Explanation of the bars is given in the legend of Additional file 10: Figure S6.
Additional file 12: Microarray data from PCLS exposed to cholestatic
model compounds. Microarray data were generated using liver slices
obtained from livers obtained from 5 mice per one experimental condition.
Abbreviations used: M1-5 stands for mouse 1–5, ctr stands for control, CsA
CyclosporinA, CPZ chlorpromazine, 24 means 24 h incubation time. Data are
normalized and presented as log2 values of intensities.Competing interests
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